Literature DB >> 8335972

Risk of human parvovirus B19 infections among school and hospital employees during endemic periods.

S P Adler1, A M Manganello, W C Koch, S H Hempfling, A M Best.   

Abstract

Because human parvovirus B19 (B19) infections are common in children, and maternal infection of pregnant women may cause fetal death, risk factors for B19 infections for hospital and school employees were identified during an endemic period. By serologic testing, 2730 employees of 135 schools in three school systems and 751 employees of a hospital were monitored. Of these, 60% were initially seropositive. After adjusting for age, race, and gender, risk factors for seropositivity were contact with children 5-18 years old at home (odds ratio [OR] = 1.2), at work (OR = 1.2), and employment in elementary schools in school system 2 (OR = 1.4). Over 42 months, 1 of 198 susceptible hospital employees seroconverted versus 62 of 927 school employees. Four factors associated with seroconversion were employment at elementary schools in system 2, contact with children 5-11 years old at home or with children 5-18 years old at work, and age < 30 years. Those in daily contact with school-age children had a fivefold increased annual occupational risk for B19 infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335972     DOI: 10.1093/infdis/168.2.361

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Quebec's safe working conditions for a Safe Maternity Experience program: survey of consultant physicians and human parvovirus B19 in Montreal-Centre.

Authors:  A T Koutsavlis; J F Boivin; R Simard; M Rossignol
Journal:  Can J Public Health       Date:  2000 Jul-Aug

Review 2.  Nosocomial spread of viral disease.

Authors:  C Aitken; D J Jeffries
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

3.  High frequency of parvovirus B19 in patients tested for rheumatoid factor.

Authors:  P Jobanputra; F Davidson; S Graham; H O'Neill; P Simmonds; P L Yap
Journal:  BMJ       Date:  1995-12-09

4.  Seroprevalence of immunoglobulin G antibody to parvovirus B19 in Ontario.

Authors:  S Wasfy; J Nishikawa; M Petric
Journal:  Can J Infect Dis       Date:  1996-09

Review 5.  Ethanol is indispensable for virucidal hand antisepsis: memorandum from the alcohol-based hand rub (ABHR) Task Force, WHO Collaborating Centre on Patient Safety, and the Commission for Hospital Hygiene and Infection Prevention (KRINKO), Robert Koch Institute, Berlin, Germany.

Authors:  Axel Kramer; Mardjan Arvand; Bärbel Christiansen; Stephanie Dancer; Maren Eggers; Martin Exner; Dieter Müller; Nico T Mutters; Ingeborg Schwebke; Didier Pittet
Journal:  Antimicrob Resist Infect Control       Date:  2022-07-06       Impact factor: 6.454

6.  Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.

Authors:  Päivi Norja; Kati Hokynar; Leena-Maija Aaltonen; Renwei Chen; Annamari Ranki; Esa K Partio; Olli Kiviluoto; Irja Davidkin; Tomi Leivo; Anna Maria Eis-Hübinger; Beate Schneider; Hans-Peter Fischer; René Tolba; Olli Vapalahti; Antti Vaheri; Maria Söderlund-Venermo; Klaus Hedman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

7.  Increased seroprevalence of IgG-class antibodies against cytomegalovirus, parvovirus B19, and varicella-zoster virus in women working in child day care.

Authors:  Gini G C van Rijckevorsel; Lian P M J Bovée; Marjolein Damen; Gerard J B Sonder; Maarten F Schim van der Loeff; Anneke van den Hoek
Journal:  BMC Public Health       Date:  2012-06-22       Impact factor: 3.295

8.  Pattern of parvovirus B 19 infection during different trimesters of pregnancy in Kuwait.

Authors:  M Makhseed; A Pacsa; M A Ahmed; S S Essa
Journal:  Infect Dis Obstet Gynecol       Date:  1999

Review 9.  Parvovirus B-19 infection during pregnancy.

Authors:  Anthony Al-Khan; Andrew Caligiuri; Joseph Apuzzio
Journal:  Infect Dis Obstet Gynecol       Date:  2003
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.